Analyst firms · Piper Sandler · REPL
Piper Sandler REPL price target and rating history
Replimune Group Inc. (REPL) · Health Care
Piper Sandler rates Replimune Group Inc. (REPL) Neutral with a $4 price target, as of its latest action on Apr 10, 2026. It has published 5 rating actions on REPL since November 2021, including 1 upgrade and 2 downgrades. Across 5 firms with a REPL price target in the last 12 months, the median target is $12. Piper Sandler's $4 is 67% below that.
- Current rating
- Neutral
- Price target
- $4
- Median target, all firms
- $12
- Actions on REPL
- 5
Piper Sandler price target on REPL
Every Piper Sandler rating on REPL
- Apr 10, 2026
- Oct 20, 2025
- Jul 22, 2025
- Apr 17, 2023
- Nov 19, 2021
How other firms rate REPL
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wedbush | Outperform | $12 | Aug 7, 2026 |
| Leerink Partners | Outperform | $17 | Aug 4, 2026 |
| Cantor Fitzgerald | Overweight | Jul 31, 2026 | |
| BMO Capital Markets | Outperform | $16 | Jun 30, 2026 |
| Jefferies | Hold | $2 | Apr 13, 2026 |
| H.C. Wainwright | Sell | Apr 13, 2026 | |
| Piper Sandler | Neutral | $4 | Apr 10, 2026 |
Questions about Piper Sandler and REPL
- What is Piper Sandler's price target for REPL?
- Piper Sandler's latest stated price target for Replimune Group Inc. (REPL) is $4, from its action on Apr 10, 2026.
- What is Piper Sandler's rating on REPL?
- Piper Sandler rates REPL Neutral, a neutral rating, as of Apr 10, 2026.
- When did Piper Sandler last change its view on REPL?
- On Apr 10, 2026, Piper Sandler downgrades to Neutral from Overweight, price target $4.
- How does Piper Sandler's REPL target compare with other analysts?
- Across 5 firms with a REPL price target in the last 12 months, the median target is $12. Piper Sandler's $4 is 67% below that.
More REPL rating histories
All Piper Sandler ratingsREPL news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.